Wolwo Pharma(SZ:300357) Cai Jing Wang·2025-10-24 03:25Core Insights - The company reported a revenue of 369 million yuan in Q3 2025, representing a year-on-year growth of 22.64% [1] - The net profit for Q3 2025 was 168 million yuan, showing a year-on-year increase of 36.44% [1] - For the first three quarters of 2025, the company achieved a total revenue of 853 million yuan, which is a 16.86% increase compared to the same period last year [1] Revenue Breakdown - The sales revenue from the product "Dust Mite Drops" was 794 million yuan, reflecting a year-on-year growth of 13.38% [1] - The sales revenue from "Artemisia Flower Pollen Allergen Sublingual Drops" reached 44.76 million yuan, marking a significant year-on-year increase of 117.58% [1] - The sales revenue from skin prick solution was 11.05 million yuan, which is a year-on-year growth of 94.10% [1] Market Strategy - The rapid growth in sales for "Artemisia Flower Pollen Allergen Sublingual Drops" and skin prick solution is attributed to the company's increased marketing efforts for these products [1]